Natalizumab Treatment of Relapsing Remitting Multiple Sclerosis Has No Long-Term Effects on the Proportion of Circulating Regulatory T Cells

INTRODUCTION: Natalizumab (NTZ), a monoclonal antibody against the integrin α4β1 (VLA-4) found on activated T cells and B cells, blocks the interaction of this integrin with adhesion molecules of central nervous system (CNS) endothelial cells and lymphocyte migration through the blood–brain barrier,...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanasescu, Radu, Frakich, Nanci, Chou, I.-Jun, Filippini, Perla, Podda, Giulio, Xin, Gao, Muraleedharan, Ranjithmenon, Jerca, Oltita, Onion, David, Constantinescu, Cris S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10630259/
https://www.ncbi.nlm.nih.gov/pubmed/37715885
http://dx.doi.org/10.1007/s40120-023-00539-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10630259/
https://www.ncbi.nlm.nih.gov/pubmed/37715885
http://dx.doi.org/10.1007/s40120-023-00539-9

Ejemplares similares